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Abstract
Background: Leishmania species are parasitic protozoa that have a tightly controlled cell cycle, regulated by cyclin-dependent
kinases (CDKs). Cdc2-related kinase 3 (CRK3), an essential CDK in Leishmania and functional orthologue of human CDK1, can
form an active protein kinase complex with Leishmania cyclins CYCA and CYC6. Here we describe the identification and
synthesis of specific small molecule inhibitors of bacterially expressed Leishmania CRK3:CYC6 using a high throughput
screening assay and iterative chemistry. We also describe the biological activity of the molecules against Leishmania parasites.
Methodology/Principal Findings: In order to obtain an active Leishmania CRK3:CYC6 protein kinase complex, we
developed a co-expression and co-purification system for Leishmania CRK3 and CYC6 proteins. This active enzyme was used
in a high throughput screening (HTS) platform, utilising an IMAP fluorescence polarisation assay. We carried out two
chemical library screens and identified specific inhibitors of CRK3:CYC6 that were inactive against the human cyclin-
dependent kinase CDK2:CycA. Subsequently, the best inhibitors were tested against 11 other mammalian protein kinases.
Twelve of the most potent hits had an azapurine core with structure activity relationship (SAR) analysis identifying the
functional groups on the 2 and 9 positions as essential for CRK3:CYC6 inhibition and specificity against CDK2:CycA. Iterative
chemistry allowed synthesis of a number of azapurine derivatives with one, compound 17, demonstrating anti-parasitic
activity against both promastigote and amastigote forms of L. major. Following the second HTS, 11 compounds with a
thiazole core (active towards CRK3:CYC6 and inactive against CDK2:CycA) were tested. Ten of these hits demonstrated anti-
parasitic activity against promastigote L. major.
Conclusions/Significance: The pharmacophores identified from the high throughput screens, and the derivatives
synthesised, selectively target the parasite enzyme and represent compounds for future hit-to-lead synthesis programs to
develop therapeutics against Leishmania species. Challenges remain in identifying specific CDK inhibitors with both target
selectivity and potency against the parasite.
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Introduction
The leishmaniases are a group of diseases caused by Leishmania,
parasitic protozoa belonging to the family Trypanosomatidae.
There are over 20 known species and sub species of Leishmania
prevalent in 88 countries worldwide. These can be grouped into
old world (Africa, Asia and Europe) and new world (the Americas)
species according to their geographic distribution. (www.who.int/
leishmaniasis/burden/en/). Several clinical forms of the disease
occur; localised cutaneous, diffuse cutaneous, mucocutaneous, and
visceral leishmaniasis. An estimated 350 million people are at risk
of infection [1] with an estimated 12 million individuals infected
worldwide. There is an annual incidence of 0.5 million of the
visceral form of the disease and 1.5–2 million cases of the
cutaneous form of the disease [2].
There are a number of drugs currently recommended for the
treatment of leishmaniasis such as the pentavalent antimonials,
Sodium stibogluconate (Pentostam, SSG) and Meglumine anti-
moniate (Glucantime); Amphotericin B and its lipid formulation
AmBisome; Pentamidine, Miltefosine (Impavido) and Paromo-
mycin [3]. Two more drugs (Imiquimod and Sitamaquine) are
currently being assessed in clinical trials. However, the current
repertoire of drugs for leishmaniasis is inadequate for a variety of
reasons; high toxicity, poor efficacy, high cost, undesirable route
of administration, narrow therapeutic window and drug resis-
tance. Indeed extensive drug resistance to the pentavalent
antimonials, has been reported in India [3]. Therefore there is
an urgent need to develop new therapeutics to treat leishmaniasis
and one area under investigation is the cell cycle and protein
kinases [4,5].
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A number of diseases are attributed to defects in protein kinase-
controlled cell signalling pathways, including cancer and inflam-
matory disease [6,7], opening up the possibility of designing
protein kinase inhibitors to rectify these defects. Indeed, Imatinib
(Gleevec), which inhibits the Ableson tyrosine kinase (Abl), is
already licensed to treat Chronic Myeloid Leukaemia (CML) [8].
Several small chemical inhibitors of cyclin-dependent kinases
(CDKs) are undergoing clinical trial to assess their effectiveness in
treating cancer. The rationale for their development stems from
the fact that dysregulation of CDK signalling in many cancers
results in unchecked proliferation [9]. Notable examples include
alvocidib (Flavopiridol) and seliciclib (CYC202 or R-roscovitine).
Alvocidib was the first CDK inhibitor to reach clinical trials [10];
it is a non-purine CDK inhibitor that inhibits a broad range of
CDKs and other intracellular targets [11,12]. It can induce cell
cycle arrest at both the G1-S and G2-M boundaries [13] and
inhibits the growth of a number of solid tumor cell lines [14].
Seliciclib is a more selective CDK inhibitor and has demonstrated
antitumour activity against human tumour xenografts [15].
Studies on the yeast and mammalian cell cycles have established
the key CDKs and cyclins that are involved in cell cycle regulation.
This work is relevant to the study of the parasite cell cycle since
homologues of many of these cell cycle regulatory proteins have
been identified in protozoan parasites, for example: CRK3 in
Leishmania [16] and T. brucei [17]; mitotic cyclins in Trypanosoma
brucei [18]. Due to their pivotal role in the cell cycle, these proteins
offer an attractive area for drug discovery and development
against trypanosomatids.
Analysis of the genome from the three trypanosomatid
protozoan parasites, L. major, T. brucei and T. cruzi, reveals that
the CDK family in trypanosomatids is relatively large, compared
with other unicellular organisms, with 11 in T. brucei and L. major
and 10 in T. cruzi. Moreover, 10 putative cyclins, CYC2-11, have
been identified in all three parasites [4]. Leishmania possess an
additional cyclin, CYCA, which is absent from both T. brucei and
T. cruzi.
As anticipated, evidence suggests that trypanosomatid CDKs
control the parasite cell cycle and that interaction with cyclins is
crucial to this activity. The L. major CDK, CRK3, can complement
a temperature sensitive S. pombe cdc2 null mutant [19],
demonstrating its functional homology to cdc2/CDK1. The gene
for L. mexicana CRK3 (99% identical to L. major CRK3) is essential,
as befits a crucial regulator of cell division. CRK3 activity was
found to peak in the G2/M phase of the cell cycle and inhibition of
CRK3 in vivo resulted in cell cycle arrest [20]. Sequence analysis
indicates that CRK3 contains residues and domains conserved in
other organisms; PSTAIRE domain, involved in cyclin binding;
Thr-14 and Tyr-15, which are required for ATP binding, and
Thr-161, the T-loop residue, phosphorylated by a CDK activating
kinase [21]. In the current study we reconstituted active
CRK3:CYC6 complex in vitro; determined the optimal peptide
substrate for the complex; adapted a high-throughput robotic
assay for use with CRK3:CYC6; screened approximately 30,000
compounds and discovered new parasite-selective pharmaco-
phores that could be developed into therapeutics to treat the
leishmaniases and shorten the drug discovery process.
Materials and Methods
Leishmania CRK3:CYC6 protein kinase complex
co-expression and co-purification
E. coli BL21 (DE3) pLys-S cells were transformed with plasmid
pGL1218 (CYC6his) and plated on an LB-agar plate with
ampicillin (50 mg ml21) and chloramphenicol (38 mg ml21) anti-
biotics. CYC6-expressing bacteria were then re-transformed with
plasmid pGL751a (CRK3his) and plated onto an LB-agar plate
supplemented with kanamycin (25 mg ml21), ampicillin
(50 mg ml21) and chloramphenicol (38 mg ml21) antibiotics. A
single colony of co-transformed E. coli BL21 (DE3) pLys-S cells
were used to inoculate 5 ml of LB-medium with kanamycin
(25 mg ml21), ampicillin (50 mg ml21) and chloramphenicol
(38 mg ml21) antibiotics and grown with agitation at 37uC
overnight. The 5 ml bacterial culture was diluted to l litre with
LB medium plus antibiotics and the culture grown at 37uC until it
reached anOD600 nm of 0.7. The 1 litre culture was then shifted to
the induction temperature of 19uC for 30 minutes and protein
expression induced with 1 mM IPTG. Cultures were induced at
19uC over night with agitation. After 16 hours, cells were
harvested at 40006 g for 15 minutes and resuspended in ice-cold
PBS pH 7.4 supplemented with DNAse-1 (10 mg ml21) (Invitro-
gen) and Lysozyme (100 mg ml21) (Sigma) for 60 minutes on ice.
The cell lysate was sonicated 4630 sec (30 sec. on/30 sec. off),
harvested at 120006 g for 20 minutes and the soluble extract
filtered through a 0.2 mm filter syringe. The proteins were purified
via BioCAD chromatography using a metal chelate Ni2+ charged
column followed by a Hiload 16/60 Superdex-200 gel filtration
column. The bacterial cell lysate was loaded onto the Ni2+ column
pre-equilibrated with wash buffer (50 mM Na2HPO4, 300 mM
NaCl pH 8.0 and 50 mM imidazole) and non-specifically bound
proteins removed by washing with the Ni2+ column wash buffer.
CRK3:CYC6 was eluted at 1 ml min21 with a linear gradient of
50–500 mM imidazole in wash buffer, over 10 column volumes
(1 column volume=1.75 ml). The fractions containing the most
protein, detected by absorbance at 280 nm, were pooled and
loaded onto a Hiload 16/60 Superdex-200 gel filtration column
pre-equilibrated with gel filtration buffer/enzyme storage buffer
(20 mM HEPES pH 7.4, 50 mM NaCl, 2 mM EGTA, 2 mM
DTT and 0.02% Brij-35). The complex was eluted at 1 ml min21
with gel filtration buffer/enzyme storage buffer and the fractions
collected. The fractions containing CRK3his and CYC6his
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proteins were determined both by Coomassie blue gel staining and
Western blot analysis and subsequently pooled together. The
pooled fractions had glycerol added to 10% of the final volume
along with Roche EDTA-free complete protease inhibitors, were
aliquoted and stored at 280uC.
Expression and purification of individual proteins
Escherichia coli BL21 (DE3) pLys-S strains were transformed with
either CRK3 plasmid DNA (pGL751a) or CYC6 plasmid DNA
(pGL1218). Transformed cells were plated onto an LB-agar plate
supplemented with kanamycin (25 mg ml21)/chloramphenicol
(38 mg ml21) for CRK3 and ampicillin (50 mg ml21)/chloram-
phenicol (38 mg ml21) for CYC6. A single colony was inoculated
into 5 ml of LB-media with the appropriate antibiotics and grown
with agitation overnight at 37uC. Bacterial cultures were bulked
up to an appropriate volume and grown at 37uC in LB-media
supplemented with the appropriate antibiotics to an optical density
of 0.7 at a wavelength of 600 nm (O.D.600 nm). Cultures were
shifted to their 19uC induction temperature for 30 mins before
protein expression was induced over night using Isopropyl-b-D-
Thiogalactopyranoside (IPTG) (300 mM for CRK3 and 1 mM for
CYC6) at 19uC. Cells were harvested at 40006 g for 15 minutes
and resuspended in ice-cold PBS, pH 7.4 supplemented with
DNAse-I (10 mg ml21) and Lysozyme (100 mg ml21) and incubat-
ed for 60 minutes on ice. The cell lysate was sonicated
5615 seconds (1 sec. on/1 sec. off) to break open the cells and
harvested at 120006g for 20 minutes. The proteins were purified
via BioCAD chromatography using a metal chelate Ni2+ charged
column. Proteins were loaded onto the Ni2+ column and the flow
through collected. The column was washed with Ni2+ column
loading/wash buffer (50 mM Na2H2PO4, 300 mM NaCl pH8.0
and 50 mM imidazole) to remove non-specific proteins bound to
the column, and the wash collected. Proteins were eluted using a
Ni2+ column elution buffer (50 mM Na2H2PO4, 300 mM NaCl
pH8.0) with a gradient of 50–500 mM imidazole over 10 column
volumes (1 column volume= 1.75 ml). For L. major CYC6 only,
Ni2+ purification was followed by purification on a strong anion
exchange Poros HQ 10 micron 4.6 mmD/100 mmL column
(Applied Biosystems). The CYC6-containing fractions were pooled
and passed through a PD-10 desalting column (Amersham) before
being loaded onto the strong anion exchange column. Proteins
were eluted using the anion exchange column elution buffer
(50 mM Tris, 5 mM EDTA pH7.0 and a 0–1 M NaCl gradient)
and the fractions collected. The identity of purified proteins were
confirmed by mass spectrometry.
Protein kinase assays
c-32P gel-based assays. Protein kinase assays were
performed using CRK3 and CYC6 cell cycle proteins in a final
volume of 20 ml. Assays were performed using the kinase assay
buffer (KAB) (50 mM MOPS, pH 7.2, 20 mM MgCl2, 10 mM
EGTA and 2 mM DTT) supplemented with 4 mM ATP, 0.5 mCi
of 3000 Ci/mmole c-32P ATP (Perkin-Elmer) per reaction and
histone H1 as a substrate used at 0.25 mg ml21. Assays were
carried out for 30 minutes at 30uC before stopping the reaction by
the addition of 7.5 ml of 46 SDS-PAGE sample buffer. The
samples were incubated at 100uC for 5 minutes and
electrophoresed on a 12% SDS-PAGE gel. Gels were processed
by staining with Coomassie blue R250 for 20 minutes, rinsing with
distilled water and destaining to remove the excess Coomassie
stain. Gels were then dried before overnight exposure to KODAK
autoradiography film for 16 hours, and developed by a Kodak X-
omat automated developer.
c-32P microtiter radiometric assays. Leishmania CRK3:
CYC6 protein kinase assays were performed in 96-well microtiter
plates in a final volume of 25 ml. Each assay point contained
7.5 ng of co-expressed histidine-tagged CRK3:CYC6 protein
kinase complex (hereafter referred to as CRK3:CYC6) diluted in
enzyme dilution buffer (EDB) (20 mM Tris-HCl pH 7.2,
0.5 mg ml21 BSA, 2.5% glycerol and 0.006% Brij-35). Assays
were performed using the assay development buffer (ADB)
(20 mM MOPS, pH 7.0, 25 mM b-glycerophosphate, 5 mM
EGTA, 1 mM NaVO3, 1 mM DTT and 15 mM MgCl2)
supplemented with 100 mM ATP, 0.5 mCi of c-32P ATP per
reaction and histone H1 as a substrate used at 0.4 mg ml21. Two
and three-fold titrations were set up to determine the
concentration of enzyme to be used per assay point (7.5 ng) and
to determine the concentrations of selected inhibitors required for
50% inhibition of Leishmania CRK3:CYC6 protein kinase activity
(IC50 values), respectively. For IC50 determinations, assay mixes
contained DMSO to a final concentration of 2%. Mammalian
protein kinase assays were carried out according to the assay
protocols developed at Cyclacel. Assays were carried out for
30 minutes at 30uC before stopping the reaction by the addition of
an equal volume (25 ml) of 75 mM orthophosphoric acid. Samples
were spotted onto a p81 cellulose filterplate (Nunc) and a vacuum
applied. Wells were washed 36200 ml with 75 mM phosphoric
acid and the bottom of the plate sealed. 50 ml of Microscint 40
(Perkin Elmer) was added per well before incorporation of
radioactivity was determined on a Topcount microplate
scintillation counter.
IMAP fluorescence polarization assays. Protein kinase
assays were performed in 384-well non-treated black plates (Nunc)
in a final volume of 20 ml. Each assay point contained 1.25 ng of
co-expressed Leishmania CRK3:CYC6 protein kinase complex.
Assays were performed using enzyme complex, 100 nM
fluorescently labelled peptide substrate (5FAM-GGGRSPG-
RRRRK-OH) (Molecular Devices), 100 mM ATP and plus or
minus an inhibitor. The enzyme complex, peptide and ATP were
made up in the IMAP complete reaction buffer (CRB) (10 mM
Tris-HCl, pH 7.2, 10 mM MgCl2, 0.05% NaN3, 0.01% Tween-
20 and 1 mM DTT). Assays were carried out for 1 hour
20 minutes at room temperature and the reaction stopped by
the addition of 50 ml of the IMAP progressive binding reagent
(Proprietary buffer from Molecular Devices plus tri-valent metal-
containing nanoparticles). The assay was left to proceed for a
further 1 hour 20 minutes at room temperature and the
fluorescence polarization determined by a Perkin Elmer Fusion
microplate reader, with excitation at 485 nm and emission at
535 nm.
Compound libraries
A compound library provided by Cyclacel under its license from
Lexicon Pharmaceuticals Inc. contained approximately 25,000
compounds composed of two sub libraries, the heterocycle 2 (HL-
2) and kinase inhibitor theme libraries. The HL-2 sub library
contained approximately 16,000 compounds and included 6
synthetic themes and 10 heterocyclic themes. These compounds
were designed to include desirable pharmaceutical properties such
as following Lipinski rules [22] and ADME (absorption,
distribution, metabolism and excretion) properties [23]. The
kinase inhibitor theme library contained approximately 8,000
and included heterocycle 1 (HL-1) compounds in addition to
published adenine, pyrimidine, quinazoline and quinoxaline
kinase inhibitors. It also comprised of natural product mimicking
compounds [24] such as sugar nucleoside mimics, protease
inhibitor themes, steroid mimics, aminoglycoside mimics and
Inhibitors of Leishmania CRK3:CYC6
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phosphatase inhibitor themes. The synthesis of novel azapurine
ligands is described in supporting information (see S3 in Text S1).
The BioFocus compound library contained 4596 compounds
and comprised of a kinase and ThemePair library (Galapagos
N.V.; www.glpg.com). The kinase library was further divided into
seven sub libraries including DFG out, hinge binding and novel
binding compounds (www.biofocus.com) [21]. The ThemePair
library contained 20 different compound scaffolds which were
fragment-like and highly soluble. Of these, the most promising sub
library was the SFK-48 kinase focused library (Galapagos N.V.)
and this was chosen for further testing against Leishmania
CRK3:CYC6. These compounds contained variable groups which
were designed in silico by BioFocus to explore the ‘DFG out’
conformation.
Molecular modelling
A model of the active cyclin-bound structure of CRK3 was built
by by aligning the sequences of LmajCRK3 (residues 1–311,
accession code O96526) with human CDK2. The alignment was
then used to build a model of the complex using the comparative
protein structure modelling program, MODELLER [25]. The
crystal structure of the human CDK2-CYCA complexed with the
small molecule inhibitor indirubin-5-sulfonate (pdb code 1E9H)
was used as the model template. Of the 20 recorded solutions, the
model with the lowest energy was used as the final model. 3D
structures of the small molecule inhibitors were built using
PRODRG [26]. Manual docking was carried out using the
program Pymol.
Parasite culture
L. major wild type promastigotes (Friedlin strain: WHO
designation MHOM/JL/81/Friedlin) were grown at 25uC in
HOMEM medium (Invitrogen cat no. 041-94699111) supple-
mented with 10% (v/v) heat inactivated foetal calf serum (HIFCS)
and 1% (v/v) penicillin/streptomycin antibiotics.
L. major promastigote growth inhibition assay
CRK3 inhibitors were diluted into HOMEM medium supple-
mented with 10% HIFCS at twice the final screening concentra-
tion. Five-fold or ten-fold serial dilutions were carried out into
HOMEM medium supplemented with 10% HIFCS. 100 ml of
each drug concentration were added to a 96 well plate in
duplicate. 100 ml of five-fold or ten-fold serial dilutions of 1 mM
Pentamidine (Sigma) and an equivalent volume of 100% DMSO
were included as positive and negative controls, in duplicate,
respectively. L. major promastigote cells were diluted to a cell
density of 26106 cells ml21 in HOMEM media supplemented
with 10% HIFCS and 100 ml added to all wells in 96 well plates.
Plates were sealed with parafilm and incubated for 5 days at 25uC.
After 5 days, 20 ml of filter sterile resazurin solution (12.5 mg
resazurin salt in 100 ml PBS) (Sigma) was added to each of the
wells and the plate incubated for a further 24 hours at 25uC.
Fluorescence was measured using an Envision plate reader (Perkin
Elmer) at 540 nm excitation wavelength and 590 nm emission
wavelength [27].
Macrophage (mW) extraction and purification
Macrophages were harvested from the peritoneum of Balb/C
mice, centrifuged at 10006 g for 10 minutes at 4uC and
resuspended in fresh RPMI 1640 media supplemented with 10%
HIFCS and 1% (v/v) Gentamicin, as described previously [28].
Macrophages were diluted to a cell density of 56105 cells ml21 in
RPMI supplemented with 10% HIFCS and 100 ml were added to
each well of a 16-well Lab-tek cavity slide (50,000 mw/well) and
incubated at 37uC, 5% CO2 for subsequent experiments.
Macrophages were infected with L. major promastigotes at a ratio
of 1:8 (macrophage:parasite) and the slides incubated for 24 hours
at 37uC with 5% CO2. Inhibitors were set up in a five-fold dilution
series in RPMI 1640 medium supplemented with 10% HIFCS.
200 ml of inhibitor were added to the wells in serial dilution and
slides incubated for 72 hours at 37uC with 5% CO2. After
72 hours the medium was removed and replaced with fresh
medium containing the same concentrations of inhibitors and
incubated for a further 48 hours at 37uC with 5% CO2. At the end
of the incubation period, the medium was removed, the slides were
washed twice with fresh RPMI 1640 medium supplemented with
10% HIFCS then fixed with 100% methanol and stained with
10% Giemsa’s stain for 10 minutes. The percentage of infected
macrophages and number of amastigotes per macrophage were
determined by light microscopy under oil immersion.
Results
Expression of active Leishmania CRK3:CYC6
Three expression systems were devised to produce an active
CRK3:CYC6 complex. Firstly, 38 kDa histidine-tagged CRK3
(CRK3his) and 35 kDa histidine tagged CYC6 (CYC6his) were
expressed and purified from E. coli individually (Fig. 1A, lanes 1
and 2) and then combined to form a complex in a 1:1 molar ratio.
Secondly, CRK3his and CYC6his were co-expressed in E. coli and
soluble protein was purified by nickel chelate and gel filtration
chromatography (Fig. 1B). In this case the CRK3his was expressed
at significantly higher levels than CYC6his, resulting in an excess
of monomeric CRK3his. Monomeric CRK3 may be able to bind
the inhibitors and thus alter their availability to bind and inhibit
the active complex, so the gel filtration step was important to
separate the CRK3:CYC6 complex from the free CRK3. This
complex was used for screening (see below). To circumvent this
problem and to provide active enzyme for detailed enzymatic
analyses (data not shown), CYC6his was co-expressed with
untagged CRK3 in E. coli and purified by Nickel chelate
chromatography and ion exchange (Fig. 1C). This resulted in a
homogenous preparation of CRK3:CYC6 complex with the
subunits found in a 1:1 molar ratio. The identities of the proteins
were confirmed by peptide mass fingerprinting and the yield of the
complex determined at ,4.5 mg litre21.
Development of a protein kinase assay for CRK3:CYC6
suitable for HTS
Leishmania CRK3 is inactive when expressed and purified as a
monomeric recombinant protein (Fig. 1D, lane 1), but is activated
to produce a histone H1 kinase in the presence of either CYCA
[29] or CYC6 (Fig. 1D, lanes 2–5). No auto-phosphorylation was
detected, so the histone H1 kinase activity of CRK3:CYC6 is not
dependent on phosphorylation of the T-loop threonine (residue
T178 in L. major CRK3) [29], as has been reported for S. cerevisiae
CDC28 [30–32] or human CDK1 [33]. A plate based radiometric
protein kinase assay using histone H1 as a substrate was developed
in order to test potential CRK3:CYC6 inhibitors. A ten-point,
two-fold enzyme titration of CRK3:CYC6 was carried out and
determined that 7.5 ng of protein complex produces a signal of
approximately 15,000 cpm at the 30 min time point, in the linear
phase of the assay, with a signal to background ratio of
approximately 15:1 (Figure S1 in Supporting Information Text
S1). This was an acceptable starting point for further assay
development and 7.5 ng of protein complex was used in all
subsequent radiometric assays. The assay was validated with a Z9
Inhibitors of Leishmania CRK3:CYC6
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score of 0.67, which is considered very good in terms of assay
quality [34,35].
The IMAP fluorescent polarisation assay was selected for the high
throughput screen. First a substrate finder assay was carried out with
61 potential serine/threonine protein kinase substrates. This revealed
that a generic sequence (GGGRSPGRRRRK) and two histone H1
derived peptides (GGGPATPKKAKKL and PKTPKKAKKL)
gave the highest fluorescence polarization signals. Several other
peptides were also found to have significant activity, including
DYRKtide RRRFRPASPLRGPPK and a CDK7 derived peptide
FLAKSFGSPNRAYKK. Analysis of the 5 peptide substrates
highlighted that they all contained a sequence pattern xS/TPxR/
K, which is in accordance with the optimal recognition motif for
CDKs, x21(S/T0)P+1x+2(K/R+3) [36] (Table 1). The generic peptide
substrate was chosen as the optimum substrate and used in all
subsequent IMAP assays. In order to establish the quantity of
CRK3:CYC6 to use in the IMAP HTS assays, a two-fold enzyme
titration was carried out (Figure S2 in Supporting Information Text
S1). This identified that 1.25 ng of kinase complex could be used per
assay point. When running the assay for 1 hour 20 minutes, this
produced a signal of approximately 280 mP with a DmP of 180 mP,
which was in the linear phase of the assay. The assay was validated
under these conditions with a Z9 score of 0.71, showing it was reliable,
robust and suitable for HTS [37].
High throughput screens of Leishmania CRK3:CYC6
As cyclin-dependent kinases are amongst the most highly
conserved protein kinases between human and Leishmania, we
reasoned that selectivity should be built into the HTS screening
protocol. Leishmania CRK3:CYC6 was screened against two
compound libraries: firstly, the Lexicon library, which comprises
a diverse set of 25,000 compounds, and secondly, the SFK48
kinase focused library from BioFocus. The first screen with the
Lexicon library identified 43 compounds that produced a $50%
inhibition of Leishmania CRK3:CYC6 protein kinase activity at
10 mM. As this library had already been screened against human
CDK2:CycA, we were able to identify 43 compounds that
inhibited the parasite enzyme, but not the human cyclin-
dependent kinase (IC50.50 mM). Six of 43 hits were identified
in follow up studies as false positive hits, whilst the remaining 37
were taken forward for IC50 determinations against CRK3:CYC6.
16 compounds had IC50 values ranging from 2.6–11 mM and 12 of
those were azapurine compounds (Table 2).
The 12 azapurines were screened against a panel of 10
mammalian protein kinases (Cdk1:CycB, Cdk4:CycD1,
Cdk7:CycH, Cdk9:CycT1, GSK-3b, Aurora A, Plk1, Ftl3, Abl
and Akt/PKB) to determine their selectivity. The 12 compounds
were inactive (at 50 mM) against 10 of the 11 protein kinases
tested. The one exception was Cdk4:CycD1, where all the
Figure 1. Expression and purification of the Leishmania CRK3:CYC6. (A) CRK3his and CYC6his were expressed in E. coli individually (lanes 1
and 2 respectively). Coomassie-stained SDS-PAGE. (B) Co-expressed CRK3his and CYC6his purified by Nickel-chelate and gel filtration
chromatography. Coomassie-stained SDS-PAGE. (C) Co-expression of CRK3 and CYC6his and purification of the CRK3:CYC6his by Nickel-chelate
and ion-exchange chromatography. Coomassie-stained SDS-PAGE. (D) Activation of CRK3his histone H1 kinase in the presence of increasing
concentrations of CYC6his. All lanes contain 1.25 mg of CRK3 and 0.025 mg, 0.05 mg, 0.075 mg, 0.1 mg of CYC6 (lanes 2–5).
doi:10.1371/journal.pntd.0001033.g001
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azapurines showed inhibitory activity at ,30 mM (Table 2). In
the absence of the structure of CRK3:CYC6, a model of the
active site of L. major CRK3 based on the human CDK2
structure provides a possible explanation for the specificity of the
binding of the azapurines. The model was built as described in
the methods section. The binding mode of kinase inhibitors has
been shown to be via a hydrogen bond donor-acceptor-donor
(D-A-D) motif that interacts with the backbone residues of
CDK2, Leu83 and Glu81, (see Figure 2d for an example).
Interestingly, the azapurine compounds have no obvious H-bond
donating atom and therefore binding to the ATP pocket must be
driven by hydrophobic interactions and accepting H-bonding
atoms from the protein. The azapurine compounds were
modelled into the CRK3 ATP site by keeping the hydrophobic
interactions of the cyclohexylmethyl moiety (an area of
conservation between CDK2 and CRK3) and placing N7 and
N8 of the triazole moiety within the limits of H-bond accepting
to the backbone of Val102 (Leu83 in CDK2). The result showed
that the O atom of the methoxybenzene group is situated in a
position whereby it is able to H-bond with Tyr101. A third weak
H-bonding interaction is predicted between an aromatic H-atom
and the backbone carbonyl of Val102. Three H-bonding
interactions are evident between CRK3 and the azapurine
inhibitors (Figure 2b and c), but the motif is changed to A-D-A.
This A-D-A binding motif is not possible in CDK2 where
Tyr101 is replaced by Phe82, which is unable to donate an H-
bonding atom. In CDK4, the tyrosine residue is replaced by
histidine (see Figure 2a for an alignment), which would still be
able to facilitate the A-D-A binding motif; therefore, the model
also explains why the azapurine compounds exhibit a lesser
selectivity for CRK3 over CDK4.
To further validate the results shown in Table 2, four of the 12
azapurine compounds were re-synthesised (3, 5, 6, and 9, Table 2,
Supporting Information Text S1). When screened against
Leishmania CRK3:CYC6, the IC50 values returned were of
24.2 mM, 4.2 mM, 4.4 mM and 37.9 mM respectively. Compared
to the original screen, compounds 5 and 6 gave comparable IC50
values, whilst compounds 3 and 9 exhibited a decrease in potency.
In order to extend the series of compounds shown in Table 2,
twenty three azapurine derivatives were synthesised (Figure 3 and
Table S1 in Supporting Information Text S1) and assayed for
Leishmania CRK3:CYC6 inhibitory activity (Table 3). Four
compounds, 13, 17, 27, and 33 returned IC50 values ,50 mM,
with 13 the most active against the complex at 15.9 mM (Table 3).
Table 1. Analysis of the peptide substrates identified from the IMAP substrate finder assay.
Peptide Sequence
Amino acid at 21
position
Amino acid at 0
position
Amino acid at +1
position DmP signal
Generic Sequence GGGRSPGRRRRK Arginine Serine Proline 310
Histone H1 derived GGGPATPKKAKKL Alanine Threonine Proline 295
Histone H1 derived (aa 9–18) PKTPKKAKKL Lysine Threonine Proline 280
DYRKtide RRRFRPASPLRGPPK Alanine Serine Proline 190
CDK7 derived FLAKSFGSPNRAYKK Glycine Serine Proline 180
The five peptides identified as substrates for CRK3:CYC6 were analysed by sequence alignment. The consensus sequence pattern follows the optimal recognition motif
identified for mammalian CDKs.
Sequence pattern: x S/T P x R/K.
Optimal recognition motif for CDKs: x21 (S/T0) P+1 x+2 (K/R+3).
Underlined are the serine/threonine amino acid residues (in the 0 position) which are phosphorylated by the CRK3:CYC6 protein kinase complex.
doi:10.1371/journal.pntd.0001033.t001
Table 2. Lexicon azapurine HTS hits.
Compound
CRK3:CYC6
IC50 (mM)
CDK4:CYCD1
IC50 (mM)
a
IC50 against WT
promastigote L. major (mM)
IC50 against WT
amastigote L. major (mM)
1 2.6 12.5 .10 .50
2 3.4 5.6 .10 38.4
3 4.4 21.9 .10 .50
4 4.4 10.3 .10 .50
5 5.3 9.7 8.6 .50
6 6.9 9.2 .10 .50
7 7.8 19.5 ND ND
8 8.1 26.9 ND ND
9 8.8 19.8 ND ND
10 10.1 7.3 ND ND
11 10.3 6.7 ND ND
12 10.7 4.6 ND ND
aAlso screened against CDK1:CYCB and CDK2:CYCA; IC50 values for all compounds in these screens were .50 mM. ND, not determined (See Table S2 in Supporting
Information Text S1 for compound structures.).
doi:10.1371/journal.pntd.0001033.t002
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Testing azapurine compounds against L. major
Eight of the most active azapurines were screened against wild
type L. major, both promastigote and amastigote life cycle stages, in
cell based assays. This highlighted two compounds with activity
towards the parasite. Compound 5, which had activity towards the
promastigote life cycle stage of Leishmania returning an IC50 value
of 8.6 mM, with no activity towards the amastigote life cycle stage
(Table 2). Conversely, compound 2 did not have activity towards
promastigote WT L. major, but did exhibit some activity towards
the amastigote life cycle stage returning an IC50 value of 38.4 mM
(Table 2).
Of the azapurine derivatives synthesised, eight compounds
showed a range of activity towards promastigote L. major: 17, 19,
27, 28, 29, 30, 31, and 34. The most potent compound against L.
major promastigotes was compound 30 with an IC50 value of
3.8 mM (Table 3). The compounds with the most activity against
intra-macrophage amastigotes were 17 and 28 with IC50 values of
5–15 mM (Table 3).
BioFocus SFK48 library HTS screen of Leishmania
CRK3:CYC6
In order to identify compounds with greater activity towards
LeishmaniaCRK3:CYC6 andWT L. major, a second HTS was carried
out with a kinase focussed chemical library, SFK48 comprising 528
compounds, from BioFocus. The library was screened against
Leishmania CRK3:CYC6 at a primary concentration of 20 mM and
counter screened against humanCDK2:CycA. Thirty six compounds
were identified which inhibited Leishmania CRK3:CYC6, a hit rate of
6.6% for this library. Of the 36 compounds, 13 were selective for
Leishmania CRK3:CYC6 versus human CDK2:CycA and were
thiazole compounds. The thiazole pharmacophore is shown in
Table 4. Further quantities of 11 compounds were repurchased from
BioFocus, seven from the 13 showing selectivity towards Leishmania
CRK3:CYC6 (table 4, compounds 36–42), and four control
compounds, two of which were active towards both CRK3:CYC6
and CDK2:CycA (compounds 43 and 44), and two that were inactive
towards both CRK3:CYC6 and CDK2:CycA (compounds 45 and
Figure 2. Predicted binding of azapurine pharmacophore and model of CRK3 active site. a) Sequence alignment of LmajCRK3, Human
CDK2 and Human CDK4 showing the percentage identity in shades of blue. The active site regions are boxed in green with key differences boxed in
red. b) A model of Lm CRK3 with an azapurine derivative (compound 11) docked in to the ATP site to show the predicted binding mode. c) Schematic
overview of the predicted binding mode of azapurine derivatives with Lm CRK3 detailing the A-D-A motif not possible in CDK2 due to the Tyr101 -
Phe82 difference. d) CDK2 binding mode with NU6102 [39] showing the D-A-D motif.
doi:10.1371/journal.pntd.0001033.g002
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46) in the primary screen. The seven compounds showing selectivity
were rescreened against CRK3:CYC6 to confirm their activity,
displaying IC50 values ranging from 3.5–10 mM (Table 4). They were
also re-screened against CDK2:CycA and all had IC50 values above
20 mM (Table 4).
Testing BioFocus SFK48 compounds against L. major
All 11 compounds were screened against promastigote WT L.
major to determine their biological activity. Ten of the compounds
exhibited activity towards WT L. major with only one returning an
IC50 value .50 mM (Table 4, compound 40). The most potent
Figure 3. Route of synthesis of the Azapurine derivatives. (i) NaN3, acetonitrile, 100uC, 90 mins; or H2SO4, NaNO2, H2O, 5uC, 10 mins, then
NaN3, hexane 5uC – RT, 2 hrs. (ii) NaOEt, ethanol, cyanoacetamide, ethyl cyclohexylacetate (or ethyl phenylacetate), 110uC, overnight. (iii) POCl3,
microwave, 130uC, 10 mins. (iv) HNR2R3, Et3N, dichloromethane, microwave, 110uC, 10 mins.
doi:10.1371/journal.pntd.0001033.g003
Table 3. Azapurine derivatives.
Compound Scaffold
CRK3:CYC6
IC50 (mM)
IC50 against WT promastigote
L. major (mM)
IC50 against WT amastigote
L. major (mM)
13 A 15.9 .50 ND
14 A .50 ND ND
15 A .50 ND ND
16 A .50 ND ND
17 A 39.1 7.4 5–15
18 A .50 ND ND
19 A .50 5–50 ND
20 A .50 ND ND
21 A .50 ND ND
22 B .50 ND ND
23 B .50 ND ND
24 A .50 ND ND
25 B .50 ND ND
26 B1 .50 ND ND
27 A 30.3 28.7 15–30
28 A .50 8.3 5–15
29 B .100 38.7 Activity at 25 mM
30 B .100 3.8 Activity at 10 mM
31 B .20 40 Activity at 25 mM
32 B .100 .50 .25
33 A 47.6 .50 .50
34 A .50 8.3 5–15
35 A .50 .50 .50
1Compound 26 contains a 4-bromo substitution on the benzyl moiety of scaffold B (See Table S3 in Supporting Information Text S1 for compound structures). ND, not
determined.
doi:10.1371/journal.pntd.0001033.t003
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compound was compound 38 with an IC50 value of 3.3 mM.
Although inactive against CRK3:CYC6, compounds 45 and 46
were active against WT promastigote L. major with IC50 values of
6.8 mM and 7.8 mM, respectively. This is most probably due to the
compounds hitting another target in Leishmania, possibly another
kinase. 10 mM compounds 36–39 and 41–46 were found to be
toxic to murine macrophages, so activity against amastigotes could
not be assessed.
Discussion
The work presented here describes the preparation of an active
leishmanial CDK complex, the development of an assay suitable
for high-throughput screening and the results of two chemical
library screens, including the identification of a new class of CRK3
inhibitor, the azapurines. Previous small scale chemical library
screens against L. mexicana CRK3 used active complex purified
from transgenic parasites, expressing a his-tagged version of
CRK3 [38]. Although this preparation was useful in the
preliminary validation of CRK3 as a potential drug target in
Leishmania, it was not suitable for high throughput screening. The
complex was only stable for short periods of time necessitating
repeated purification, introducing the possible complication of
batch to batch variation. Moreover, CRK3 purified from
transgenic Leishmania was a heterogeneous mix, likely to contain
both monomer and complex, in unknown proportions. In
addition, CRK3 is known to bind at least two cyclins (CYCA
and CYC6) and it may also be present in more than one
phosphorylation state (which would be predicted to both activate
and inactivate the complex). Since we could not characterise or
control the relative proportions of each component in this
heterogeneous mixture, we sought alternative ways in which to
produce active CRK3 complex. Since L. mexicana CRK3 has been
shown to function predominantly in the G2/M phase of the cell
cycle [20] and CYC6 in T. brucei was the mitotic cyclin partner for
TbCRK3, we focused on the leishmanial homologue of TbCYC6
[4].
Initially, CRK3 and CYC6 were expressed (his-tagged) and
purified separately in bacteria. These were then combined in vitro
and found to form an active complex. Once it was established that
CYC6 could bind and activate CRK3, we pursued the co-
expression of CRK3his and CYC6his together in bacteria, in an
attempt to overcome the low expression of CYC6 when expressed
on its own (Figure 1A, lane 2). This approach was successful, but
because both subunits were his-tagged and CRK3 was expressed
at higher concentrations, the resultant purified preparation
contained an excess of CRK3 (Figure 1B) and therefore consisted
of a mixture of complex and monomer. The complex was
separated from monomer by gel filtration chromatography and
was used to perform the library screens. Subsequently, we co-
expressed his-tagged CYC6 and non-tagged CRK3, purifying
initially by Ni-chelate column chromatography, such that
CYC6his, and CRK3 in complex with the cyclin, would be
retained on the column whilst monomer CRK3 would be eluted.
The resultant preparation is a 1:1 molar ratio of CRK3 and CYC6
(Figure 1C), was extremely stable on storage and is being used to
attempt to crystallise the complex. Unfortunately, despite assessing
a wide range of conditions, no CRK3:CYC6 crystals have been
obtained to date.
Once a defined and reproducible source of active CRK3 had
been established, assays were developed, both radiometric and
fluorescence polarisation. The IMAP fluorescence polarisation
assay was chosen to screen the chemical libraries because it
required 6 times less enzyme per reaction than the radiometric
assay and because a fluorescence based platform is more suitable
for an HTS campaign. A number of peptide substrates were
phosphorylated by CRK3 but all of them complied with the
consensus phosphorylation pattern for CDKs: x21(S/
T0)P+1x+2(K/R+3) [36], indicating that the recognition and
phosphor-transfer mechanism is conserved in the leishmanial
CDK.
Both chemical library screens (Lexicon and BioFocus SFK48)
yielded inhibitors of CRK3. CRK3 was screened against the
25,000 compound Lexicon library at a single 10 mM concentration
and counter screened against CDK2:CycA. Only specific
inhibitors of Leishmania CRK3 were sought, as a previous small
scale screen of anti-mitotic compounds had identified many CRK3
inhibitors, but none that had specificity in comparison with
mammalian CDK homologues [38]. 37 compounds were
confirmed as inhibitors of CRK3. Twelve of the most potent
CRK3 inhibitors were azapurine compounds. Comparison of
these active azapurine compounds with other azapurine com-
pounds in the library which did not inhibit CRK3 revealed that
the active compounds all had a methoxybenzene group at the 9-
position and a cyclohexylmethyl group at position 2 (Table 2).
Interestingly, during counter-screening, these compounds were
also found to be inactive against 10 out of 11 mammalian kinase
enzymes tested, with the exception of CDK4/CycD1. Modelling
of the azapurine compounds into the active site of CRK3 revealed
a possible explanation for this selective inhibition of the parasite
kinase. Instead of the normal donor-acceptor-donor binding motif
used by other kinase inhibitors, the azapurines are predicted to
bind to CRK3 using an acceptor-donor-acceptor (A-D-A) motif,
which is not possible in the mammalian protein kinases tested
(apart from CDK4/CycD1), see Figure 2. Moreover, this binding
motif is consistent with the requirement for a methoxybenzene
group at position 9, which is involved in hydrogen bonding to
Tyr101, and with the requirement for the non-polar cyclohex-
ylmethyl group at position 2, which can then form hydrophobic
interactions with the hydrophobic pocket (Figure 2b and 2c).
Although all the azapurine CRK3 inhibitors also inhibited
CDK4/CycD1, the relative potencies toward the 2 enzymes
varied between compounds. For instance, compound 2 was
equally active against both CRK3 and CDK4/CycD1 but
compound 12 was more potent against the mammalian CDK
Table 4. BioFocus SFK48 HTS hits.
Compound
CRK3:CYC6
IC50 (mM)
CDK2:CYCA
IC50 (mM)
IC50 against WT
promastigote
L. major (mM)
36 3.5 .20 26.8
37 4.8 .20 27.5
38 5.0 .20 3.3
39 7.5 .20 3.8
40 7.8 .20 .50
41 9.0 .20 26.1
42 10.0 .20 6.9
43 ND ND 12.5
44 ND ND 14.4
45 ND ND 6.8
46 ND ND 7.8
ND, not determined. (See Table S3 in Supporting Information Text S1 for
compound structures).
doi:10.1371/journal.pntd.0001033.t004
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(Table 2). Since all the Lexicon azapurines in Table 2 have a
methoxybenzene at position 9 and cyclohexylmethyl at position 2,
they differ only in their substituent group at position 6 (Table 2)
implying that the small differences in potency of these compounds
towards CRK3 and CDK4/CycD1 must be due to differences in
the ‘‘deep cleft’’ of these two kinases. This opens up the possibility
of exploiting these differences to design an azapurine inhibitor
with more favourable parasite selectivity.
A number of other azapurine derivatives were synthesised in
order to explore further the azapurine scaffold and test the binding
hypothesis. None of these derivatives were more potent than the
original hits from the chemical library screen. They did, however,
provide some useful structure activity data. In compound 33
(Table 3), the methoxybenzene group at position 9 was successfully
replaced with a fluorobenzene group, in which the electronegative
fluorine can act as a hydrogen bond acceptor in place of the
oxygen of the methoxybenzene, thus maintaining the A-D-A
binding motif. Introduction of an additional methyl group between
the azapurine core structure and the methoxybenzene ring
resulted in loss of the CRK3-inhibitory activity – compare
compounds 13 with 14 and 20 with 27. This can be explained
with reference to the A-D-A binding motif, in that the introduction
of an additional methyl group, would shift the position of the
oxygen atom of the methoxybenzene group such that it could no
longer act as an efficient hydrogen bond acceptor from the
hydroxyl group of Tyr101 (Figure 2b an 2c). Replacement of the
cyclohexylmethyl group at position 2 with the aromatic methyl-
benzene ring resulted in a dramatic decrease in the CRK3
inhibitory activity – compare compound 31 in Table 3
(IC50.20 mM), with compound 6, Table 2 (IC50 = 6.9 mM).
Although methylbenzene should also be capable of making
hydrophobic interactions with the hydrophobic pocket, it would
have a considerably different 3D-shape from the cycloalkane ring.
A benzene ring is planar in structure, whilst the cyclohexyl ring
normally adopts a contorted, energetically-favourable ‘‘chair’’
conformation. Perhaps the shape of the cyclohexyl ring is more
‘‘complimentary’’ to the shape of the hydrophobic pocket and thus
is more favourable for interaction with CRK3.
The azapurine compounds were also tested against the parasite
in culture; both insect-stage promastigotes and intra-macrophage
amastigotes. Only one of the Lexicon azapurine compounds had
any activity against the parasite in vitro (compound 5, IC50 versus
promastigotes = 8.6 mM, Table 2). Of the azapurine derivatives
depicted in Table 3, few inhibited parasite growth in culture (17,
27, 28, 29 and 30). Some of these compounds did not inhibit
CRK3/CYC6 in vitro, indicating that the drug target in the
parasite was unlikely to be CRK3 (Table 3, compounds 28, 29 and
20). Despite being relatively selective CRK3 inhibitors, none of the
azapurine compounds displayed potent anti-parasite activity. The
IC50 values for the compounds were in the micromolar range;
perhaps they were not potent enough CRK3 inhibitors to be able
to have an effect at the whole cell level. Or they may not have
been able to achieve sufficiently high intracellular concentration to
have an inhibitory effect on CRK3 in vivo. Further modification of
the azapurine scaffold may yet achieve inhibitors with the correct
profile of CRK3 selectivity, cell permeability and anti-parasite
activity.
The screening of the second chemical library, BioFocus SFK48,
yielded a better ‘‘hit rate’’ with 6.6% of compounds being
identified as CRK3 inhibitors. This is perhaps unsurprising since
this was a kinase-focused library. Of the original 36 hits, 13
compounds were identified that selectively inhibited CRK3 more
than human CDK2; these compounds all contained the thiazole
scaffold (Table 4). A number of thiazole compounds were tested
against promastigote L. major and most were found to have
moderate anti-parasite activity. However, there was no correlation
between the activity against the parasite and activity against the
purified CRK3:CYC6 enzyme complex. This might be due to
differing cell permeability or because the observed effects are not
due to CRK3 inhibition alone. Indeed, two compounds that did
not inhibit CRK3 could inhibit parasite replication in vitro. Clearly,
their effects are not due to inhibition of CRK3 and are most likely
due to the inhibition of another protein kinase in the parasite.
More work needs to be done to establish whether the growth
inhibitory effects of the thiazole CRK3 inhibitors is due to
inhibition of CRK3 in vivo, either partially or wholly.
In this study, CRK3:CYC6 cyclin-dependent kinase selective
inhibitors were identified, yet poor correlation was observed
between potency against the target and anti-parasite activity.
Optimisation of the two series of compounds will be required to
increase potency of the compounds against CRK3:CYC6, so that
an assessment can be made of the potential of the azapurines and
thiazoles to be developed into lead compounds for anti-leishmanial
drug development activities. It remains an open question whether
selectivity for the parasite target should be a priority in selection
protocols for HTS screening programs, or whether potent
inhibitors should be first identified and then selectivity sought in
subsequent chemistry optimisation.
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